Synthesis and in vivo Antihyperlipidemic Potential of Novel Substituted Thieno[3,2-d]pyrimidines

被引：0

作者：

Tamboli, Riyaj Shaukat ^{[1
]}

Amrutkar, Rakesh Devidas ^{[2
]}

Jain, Kishor Sanchlal ^{[3
]}

Kathiravan, Muthu Kumaradoss ^{[3
]}

机构：

[1] Maharaja Sayajirao Univ Baroda, Fac Technol & Engn, Dept Pharm, Vadodara 390001, Gujarat, India

[2] MGVs Samajshree Prashantdada Hiray Coll Pharm, Dept Pharmaceut Chem, Malegaon 423105, Maharashtra, India

[3] STESs Sinhgad Coll Pharm, Pune 411041, Maharashtra, India

来源：

LETTERS IN DRUG DESIGN & DISCOVERY | 2013年 / 10卷 / 09期

关键词：

Antihyperlipidemic agents; Gemfibrozil; Lipid profile; Synthesis; Thieno[3,2-d]pyrimidines; Vitamin B-3; ACIDIC CONDITIONS; NITRILES; PRODRUGS; DISEASE; DESIGN; ESTERS;

D O I：

暂无

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A novel series of substituted thieno[3,2-d]pyrimidin-4(3H) ones 7-22 has been synthesized and evaluated for in vivo antihyperlipidemic activity using Triton WR 1339. Out of the 16 compounds synthesized and tested, 8 compounds have shown significant effect on total lipid profile. These compounds are several times more potent than gemfibrozil, the standard drug used for comparison. The superior activity of compounds 16 and 19 may be because of their esterase mediated metabolism into active metabolites. These compounds may serve to be ideal leads to provide newer antihyperlipidemic agents.

引用

页码：906 / 915

页数：10

共 36 条

[21]

Lee JH, 2008, B KOREAN CHEM SOC, V29, P2491

[22]

Otera J., 2003, ESTERIFICATION METHO, P303

[23]

Roger VL, 2012, CIRCULATION, V125, pE2, DOI [10.1161/CIR.0b013e31823ac046, 10.1161/CIR.0b013e3182456d46]

[24]

Saito Y., 1993, European Patent Appl, Patent No. 535548

[25]

SAUTER F, 1978, SAUTER F, V89

[26]

SAUTER F, 1992, SCI PHARM, V116, P23537

[27]

SAUTER F, 1980, SAUTER F, V92

[28]

SAUTER F, 1972, Patent No. 2210503

[29]

SHAW JE, 1973, TETRAHEDRON LETT, P689

[30]

SHIROKI M, 1976, Patent No. 1974116710

← 1 2 3 4 →